1. Home
  2. UNCY vs CATO Comparison

UNCY vs CATO Comparison

Compare UNCY & CATO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UNCY
  • CATO
  • Stock Information
  • Founded
  • UNCY 2016
  • CATO 1946
  • Country
  • UNCY United States
  • CATO United States
  • Employees
  • UNCY N/A
  • CATO N/A
  • Industry
  • UNCY Biotechnology: Pharmaceutical Preparations
  • CATO Clothing/Shoe/Accessory Stores
  • Sector
  • UNCY Health Care
  • CATO Consumer Discretionary
  • Exchange
  • UNCY Nasdaq
  • CATO Nasdaq
  • Market Cap
  • UNCY 58.7M
  • CATO 63.9M
  • IPO Year
  • UNCY 2021
  • CATO N/A
  • Fundamental
  • Price
  • UNCY $0.55
  • CATO $3.25
  • Analyst Decision
  • UNCY Strong Buy
  • CATO
  • Analyst Count
  • UNCY 3
  • CATO 0
  • Target Price
  • UNCY $6.50
  • CATO N/A
  • AVG Volume (30 Days)
  • UNCY 925.3K
  • CATO 108.7K
  • Earning Date
  • UNCY 05-12-2025
  • CATO 03-20-2025
  • Dividend Yield
  • UNCY N/A
  • CATO 10.63%
  • EPS Growth
  • UNCY N/A
  • CATO N/A
  • EPS
  • UNCY N/A
  • CATO N/A
  • Revenue
  • UNCY N/A
  • CATO $649,806,000.00
  • Revenue This Year
  • UNCY N/A
  • CATO N/A
  • Revenue Next Year
  • UNCY $888.72
  • CATO N/A
  • P/E Ratio
  • UNCY N/A
  • CATO N/A
  • Revenue Growth
  • UNCY N/A
  • CATO N/A
  • 52 Week Low
  • UNCY $0.20
  • CATO $2.64
  • 52 Week High
  • UNCY $1.60
  • CATO $6.70
  • Technical
  • Relative Strength Index (RSI)
  • UNCY 49.02
  • CATO 51.46
  • Support Level
  • UNCY $0.57
  • CATO $2.87
  • Resistance Level
  • UNCY $0.65
  • CATO $4.00
  • Average True Range (ATR)
  • UNCY 0.05
  • CATO 0.39
  • MACD
  • UNCY -0.00
  • CATO 0.06
  • Stochastic Oscillator
  • UNCY 28.20
  • CATO 44.54

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.

About CATO Cato Corporation (The)

The Cato Corp operates as a specialty retailer of fashion apparel and accessories primarily in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.

Share on Social Networks: